



STIC SEARCH RESULTS FEEDBACK FORM

Biotech-Chem Library

Questions about the scope or the results of the search? Contact *the searcher or contact*:

Mary Hale, Information Branch Supervisor
Remsen Bldg. 01 D86
571-272-2507

Voluntary Results Feedback Form

➤ I am an examiner in Workgroup: Example: 1610

➤ Relevant prior art **found**, search results used as follows:

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
(journal articles, conference proceedings, new product announcements etc.)

➤ Relevant prior art **not found**:

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC-Biotech-Chem Library Remsen Bldg.



this page blank (uspio)

FOR OFFICIAL USE ONLY

170935

ACCESS DB #

PLEASE PRINT CLEARLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: MARK BERCH Examiner #: 59193 Date: 11/18/05
 Art Unit: 1624 Phone Number: 2-0663 Serial Number: 10689381
 Location (Bldg/Room#): 5C01 (Mailbox #): 5C18 Results Format Preferred (circle): PAPER DISK

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: _____

Inventors (please provide full names): _____



Earliest Priority Date: _____

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

to combine
with
4728644



I Reference has anti-inflammatory, antipyretic, analgesic
 anti allergy or "platelet aggregation"

$R_2 = H / \text{alkyl}$ $R_8 = Q$
 $R_6 = N\text{-in-a-ring}$

- II Compound with $R_9 = \text{alkyl}$, and two of these conditions met (3rd can be anything)
- III Compound with $R_9 = Q$, and two of these conditions met

I need Biblos which satisfy I, II & III. Print out the hit species for II and III

RECEIVED
 NOV - 8 2005
 STIC

This Page Blank (usp10)

=> fil reg; d stat que l42
FILE=REGISTRY' ENTERED AT 16:15:24 ON 18 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 17 NOV 2005 HIGHEST RN 868355-11-7
DICTIONARY FILE UPDATES: 17 NOV 2005 HIGHEST RN 868355-11-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

L5 232082 SEA FILE=REGISTRY ABB=ON 333.446/RID
L8 STR




VAR G1=C/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS 6

STEREO ATTRIBUTES: NONE


L9 STR



VAR G1=C/N
 VAR G2=O/S/N
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC I
 NUMBER OF NODES IS 5



STEREO ATTRIBUTES: NONE
 L38 STR



VAR G2=H/13
 NODE ATTRIBUTES:
 CONNECT IS E1 RC AT 12
 CONNECT IS E1 RC AT 13
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS M1 N AT 10

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE
 L39 STR




VAR G2=H/13
 VAR G10=32/21
 NODE ATTRIBUTES:

*Hy = heterocycle
 containing at
 least 1 nitrogen*



CONNECT IS E1 RC AT 13
 CONNECT IS E1 RC AT 26
 CONNECT IS E1 RC AT 38
 DEFAULT MLEVEL IS ATOM
 GGCAT IS MCY UNS AT 39
 GGCAT IS MCY UNS AT 40
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS M1 N AT 24

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 26

STEREO ATTRIBUTES: NONE
 L40 STR



Ak @13 G10 14



VAR G2=H/13
 VAR G10=7/32/21
 NODE ATTRIBUTES:
 CONNECT IS E1 RC AT 13
 DEFAULT MLEVEL IS ATOM
 GGCAT IS MCY UNS AT 12
 GGCAT IS MCY UNS AT 26
 GGCAT IS MCY UNS AT 38
 GGCAT IS MCY UNS AT 39
 GGCAT IS MCY UNS AT 40
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS M1 N AT 10
 ECOUNT IS M1 N AT 24

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 38

STEREO ATTRIBUTES: NONE

L42 864 SEA FILE=REGISTRY SUB=L5 SSS FUL ((L38 OR ((L39 OR L40) AND (L8 OR L9)))

100.0% PROCESSED 180237 ITERATIONS
 SEARCH TIME: 00.00.10

864 ANSWERS

=> fil capl; d que nos l43; fil uspatf; d que nos l46; fil toxcenter; d que nos l48; dup rem l43,l46,l48
FILE 'CAPLUS' ENTERED AT 16:15:46 ON 18 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Nov 2005 VOL 143 ISS 22
FILE LAST UPDATED: 17 Nov 2005 (20051117/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L5	232082	SEA FILE=REGISTRY ABB=ON	333.446/RID
L8		STR	
L9		STR	
L16	37939	SEA FILE=CAPLUS ABB=ON	ANTI-INFLAMMATORY AGENTS/CT
L17	87526	SEA FILE=CAPLUS ABB=ON	INFLAMMATION/CW
L18	49905	SEA FILE=CAPLUS ABB=ON	ANALGES?/OBI
L19	9202	SEA FILE=CAPLUS ABB=ON	ALLERGY INHIBITORS/CT
L20	4955	SEA FILE=CAPLUS ABB=ON	ANTIPYRETICS/CT
L21	22330	SEA FILE=CAPLUS ABB=ON	PLATELET#/OBI (L) AGGREGAT?/OBI
L38		STR	
L39		STR	
L40		STR	
L42	864	SEA FILE=REGISTRY SUB=L5 SSS FUL (L38 OR ((L39 OR L40) AND (L8 OR L9)))	
L43	11	SEA FILE=CAPLUS ABB=ON L42 AND (L16 OR L17 OR L18 OR L19 OR L20 OR L21)	

FILE 'USPATFULL' ENTERED AT 16:15:47 ON 18 NOV 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 17 Nov 2005 (20051117/PD)
FILE LAST UPDATED: 17 Nov 2005 (20051117/ED)
HIGHEST GRANTED PATENT NUMBER: US6966066
HIGHEST APPLICATION PUBLICATION NUMBER: US2005257307
CA INDEXING IS CURRENT THROUGH 17 Nov 2005 (20051117/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 17 Nov 2005 (20051117/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2005


```

>>> USPAT2 is now available.  USPATFULL contains full text of the  <<<
>>> original, i.e., the earliest published granted patents or  <<<
>>> applications.  USPAT2 contains full text of the latest US  <<<
>>> publications, starting in 2001, for the inventions covered in  <<<
>>> USPATFULL.  A USPATFULL record contains not only the original  <<<
>>> published document but also a list of any subsequent  <<<
>>> publications.  The publication number, patent kind code, and  <<<
>>> publication date for all the US publications for an invention  <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL  <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc.  <<<

>>> USPATFULL and USPAT2 can be accessed and searched together  <<<
>>> through the new cluster USPATALL.  Type FILE USPATALL to  <<<
>>> enter this cluster.  <<<
>>>  <<<
>>> Use USPATALL when searching terms such as patent assignees,  <<<
>>> classifications, or claims, that may potentially change from  <<<
>>> the earliest to the latest publication.  <<<

```

This file contains CAS Registry Numbers for easy and accurate substance identification.

```

L5      232082 SEA FILE=REGISTRY ABB=ON  333.446/RID
L8      STR
L9      STR
L31     33986 SEA FILE=USPATFULL ABB=ON  (ANTIINFLAMM? OR INFLAMM?)/IT,TI,AB,
      CLM
L32     2341 SEA FILE=USPATFULL ABB=ON  (ANTIPYRETIC? OR PYRETIC? OR
      ANTIPHLOGISTIC? OR PHLOGISTIC? OR ANTITHERMIC? OR THERMIC?)/IT,
      TI,AB,CLM
L33     11382 SEA FILE=USPATFULL ABB=ON  ANALGES?/IT,TI,AB,CLM
L34     11903 SEA FILE=USPATFULL ABB=ON  (ALLERG? OR ANTIALLERG?)/IT,TI,AB,CL
      M
L35     3813 SEA FILE=USPATFULL ABB=ON  (PLATELET#(3A)AGGREGAT?)/IT,TI,AB,CL
      M
L38     STR
L39     STR
L40     STR
L42     864 SEA FILE=REGISTRY SUB=L5 SSS FUL (L38 OR ((L39 OR L40) AND (L8
      OR L9)))
L45     31 SEA FILE=USPATFULL ABB=ON  L42
L46     7 SEA FILE=USPATFULL ABB=ON  L45 AND (L31 OR L32 OR L33 OR L34
      OR L35)

```

FILE TOXCENTER ENTERED AT 16:15:47 ON 18 NOV 2005
 COPYRIGHT (C) 2005 ACS

FILE COVERS 1907 TO 15 Nov 2005 (20051115/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TOXCENTER has been enhanced with new files segments and search fields.
See HELP CONTENT for more information.

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary. See <http://www.nlm.nih.gov/mesh/> and http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html for a description of changes.

```
L5      232082 SEA FILE=REGISTRY ABB=ON  333.446/RID
L8      STR
L9      STR
L24     193631 SEA FILE=TOXCENTER ABB=ON  ?INFLAMM?
L25     19392  SEA FILE=TOXCENTER ABB=ON  ?PYRETIC? OR ?PHLOGISTIC? OR
        ?THERMIC?
L26     56964 SEA FILE=TOXCENTER ABB=ON  ANALGES?
L27     101949 SEA FILE=TOXCENTER ABB=ON  ?ALLERG?
L28     15784 SEA FILE=TOXCENTER ABB=ON  PLATELET? (3A) AGGREGAT?
L38     STR
L39     STR
L40     STR
L42     864   SEA FILE=REGISTRY SUB=L5 SSS FUL (L38 OR ((L39 OR L40) AND (L8
        OR L9)))
L44     122   SEA FILE=REGISTRY ABB=ON  L42 AND TOXCENTER/LC
L47     17    SEA FILE=TOXCENTER ABB=ON  L44
L48     3     SEA FILE=TOXCENTER ABB=ON  L47 AND (L24 OR L25 OR L26 OR L27
        OR L28)
```

FILE 'CAPLUS' ENTERED AT 16:15:47 ON 18 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:15:47 ON 18 NOV 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 16:15:47 ON 18 NOV 2005
COPYRIGHT (C) 2005 ACS
PROCESSING COMPLETED FOR L43
PROCESSING COMPLETED FOR L46
PROCESSING COMPLETED FOR L48
L49 17 DUP REM L43 L46 L48 (4 DUPLICATES REMOVED)
 ANSWERS '1-11' FROM FILE CAPLUS
 ANSWERS '12-17' FROM FILE USPATFULL

=> d ibib ed abs hitstr 1-17; fil hom



```
L49  ANSWER 1 OF 17  CAPLUS  COPYRIGHT 2005 ACS on STN DUPLICATE 1
ACCESSION NUMBER:    2005:612301  CAPLUS
DOCUMENT NUMBER:     143:153230
TITLE:               Preparation of substituted purines and other bicyclic
                    heterocycles as p-38 kinase inhibitors
INVENTOR(S):         Dong, Qing; Wang, Jianqiang; Lan, Jiong; Lang,
                    Hengyuan
PATENT ASSIGNEE(S):  Triad Therapeutics, Inc., USA; Novartis Pharma AG
SOURCE:              PCT Int. Appl., 149 pp.
                    CODEN: PIXXD2
DOCUMENT TYPE:       Patent
```

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063766	A2	20050714	WO 2004-US43682	20041223
WO 2005063766	A3	20050909		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2003-532529P P 20031223
 US 2004-575113P P 20040528

OTHER SOURCE(S): MARPAT 143:153230
 ED Entered STN: 15 Jul 2005
 GI



AB The present invention discloses preparation of bicyclic heterocyclic compds., such as I [R¹ = halo, alkyl, cycloalkyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, NR₄R₅, OR₄; R² = alkyl, cycloalkyl, halo, trifluoromethyl, trifluoromethoxy, CN, NR₄R₅, OR₄, etc.; R³ = H, alkyl, cycloalkyl, OR₄, heteroaryl, heterocycle; R₄, R₅ = H, alkyl, cycloalkyl; n = 0-2; Y = C(:O)NH, NHC(:O), NHC(:O)NH, SO₂NH, NHSO₂, CO; X¹ = single bond, alkylene, O, S, SO₂, CO, CONH; A = bicyclic heterocycle; X² = single bond, alkylene, O, S, NH, alkylamino, SO₂, CO, CONH; D = monocyclic or bicyclic aromatic or nonarom. ring containing up to four heteroatoms], or a pharmaceutically acceptable derivs. thereof, for their therapeutic use as p38 kinase, including p38 α and p38 β kinase, inhibitors. Thus, N-cyclopropyl-3-hydrazino-4-methyl-benzamide (also prepared) was reacted with aminomalononitrile p-toluene sulfonate to afford 3-(5-amino-4-cyano-

imidazol-1-yl)-N-cyclopropyl-4-methyl-benzamide, which on reaction with phenylmagnesium bromide, provided 3-(5-amino-4-benzoyl-imidazol-1-yl)-N-cyclopropyl-4-methyl-benzamide (II). A mixture of benzamide derivative II, formamide and acetic acid was heated in the microwave to afford purine derivative III. Pharmaceutical compns. containing I are also provided.

Methods

of treatment, prevention or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders are also provided.


IT 858358-31-3P 858358-34-6P 858358-36-8P
 858358-57-3P 858358-58-4P 858358-59-5P
 858358-60-8P 858358-61-9P 858358-69-7P
 858358-70-0P 858358-71-1P 858358-73-3P
 858358-79-9P 858358-89-1P 858358-91-5P
 858358-97-1P 858359-03-2P 858359-07-6P
 858359-09-8P 858359-11-2P 858359-12-3P
 858359-13-4P 858359-15-6P 858359-16-7P
 858359-17-8P 858359-18-9P 858359-19-0P
 858359-20-3P 858359-21-4P 858359-28-1P
 858359-32-7P 858359-33-8P 858359-34-9P
 858359-50-9P 858359-51-0P 858359-52-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted purines and other bicyclic heterocycles as p-38 kinase inhibitors for the treatment of inflammatory disease, autoimmune disease etc.)


RN 858358-31-3 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-(6-methoxy-3-pyridinyl)-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 858358-34-6 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(5-pyrimidinyl)-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858358-36-8 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(3-pyridinyl)-9H-purin-9-yl]- (9CI)
(CA INDEX NAME)


RN 858358-57-3 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(4-methyl-1-piperidinyl)-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858358-58-4 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(3-methyl-1-piperidinyl)-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858358-59-5 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-(hexahydro-1(2H)-azocinyl)-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 858358-60-8 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(1-pyrrolidinyl)-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858358-61-9 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-(hexahydro-1H-azepin-1-yl)-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 858358-69-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[9-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-9H-purin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 858358-70-0 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[9-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-9H-purin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 858358-71-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-[9-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-9H-purin-6-yl]- (9CI) (CA INDEX NAME)




RN 858358-73-3 CAPLUS

CN 3-Piperidinecarboxamide, 1-[9-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-9H-purin-6-yl]- (9CI) (CA INDEX NAME)




RN 858358-79-9 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-(2-ethyl-1-piperidinyl)-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 858358-89-1 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(2-methyl-1-pyrrolidinyl)-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858358-91-5 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(tetrahydro-1,4-oxazepin-4(5H)-yl)-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858358-97-1 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)



RN 858359-03-2 CAPLUS


CN Benzamide, N-cyclopropyl-3-[6-(3-fluoro-1-piperidinyl)-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)



RN 858359-07-6 CAPLUS


CN Benzamide, N-cyclopropyl-3-[6-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 858359-09-8 CAPLUS


CN Benzamide, 3-[6-[3-(acetylamino)-1-pyrrolidinyl]-9H-purin-9-yl]-N-cyclopropyl-4-methyl- (9CI) (CA INDEX NAME)



RN 858359-11-2 CAPLUS



CN 2-Pyrrolidinecarboxamide, 1-[9-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-9H-purin-6-yl]-N,N-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 858359-12-3 CAPLUS


CN Benzamide, 3-[6-(7-azabicyclo[2.2.1]hept-7-yl)-9H-purin-9-yl]-N-cyclopropyl-4-methyl- (9CI) (CA INDEX NAME)



RN 858359-13-4 CAPLUS


CN Benzamide, N-cyclopropyl-3-[6-[(2R,5R)-2,5-dimethyl-1-pyrrolidinyl]-9H-purin-9-yl]-4-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 858359-15-6 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(1-piperidinyl)-9H-purin-9-yl]-(9CI) (CA INDEX NAME)




RN 858359-16-7 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(4-morpholinyl)-9H-purin-9-yl]-(9CI) (CA INDEX NAME)




RN 858359-17-8 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-(4-ethyl-1-piperazinyl)-9H-purin-9-yl]-4-methyl-(9CI) (CA INDEX NAME)




RN 858359-18-9 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(2-methyl-1-piperidinyl)-9H-purin-9-yl]-(9CI) (CA INDEX NAME)




RN 858359-19-0 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-(2,6-dimethyl-4-morpholinyl)-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 858359-20-3 CAPLUS

CN Benzamide, 3-[6-(4-acetyl-1-piperazinyl)-9H-purin-9-yl]-N-cyclopropyl-4-methyl- (9CI) (CA INDEX NAME)




RN 858359-21-4 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(4-methyl-1-piperazinyl)-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858359-34-9 CAPLUS

CN Benzamide, 3-[6-[3-(acetilmethylamino)-1-pyrrolidinyl]-9H-purin-9-yl]-N-cyclopropyl-4-methyl- (9CI) (CA INDEX NAME)




RN 858359-50-9 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(2-pyridinyl)-9H-purin-9-yl]- (9CI)
(CA INDEX NAME)




RN 858359-51-0 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(2-pyrimidinyl)-9H-purin-9-yl]- (9CI) (CA INDEX NAME)



RN 858359-52-1 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(2-thiazolyl)-9H-purin-9-yl]- (9CI)
(CA INDEX NAME)



L49 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2004:650871 CAPLUS

DOCUMENT NUMBER: 141:174185

TITLE: Preparation of purines and pyrrolopyrimidines as selective kinase inhibitors

PATENT ASSIGNEE(S): Merckle GmbH, Germany

SOURCE: Eur. Pat. Appl., 64 pp.

CODEN: EPXXDW


DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1444982	A1	20040811	EP 2003-2753	20030206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			EP 2003-2753	20030206
OTHER SOURCE(S): MARPAT 141:174185				
ED Entered STN: 13 Aug 2004				
GI				




AB Title compds. [I; R1 = H, halo, alkoxy, (substituted) PhNH, PhO, PhCH2S, PhS, Ph, PhCH2, styryl, etc.; R2 = H, alkyl; X = N, NR3; Y = N, CR5, NR6; 1 dotted line = double bond, the other = single bond; R3 = H, alkyl, (substituted) Ph, PhCH2; R4 = H, halo, C.tplbond.C(CH2)mOH, (substituted) Ph; m = 1-3; R5 = H; R6 = H, (substituted) Ph, PhCH2], were prepared as selective kinase inhibitors. Thus, 6-chloro-9H-purine, PhNH2, and Et3N were refluxed 4.5 h in BuOH to give 76% N-phenyl(9H-purin-6-yl)amine. This at 30 μ M gave 34% inhibition of SAPK2a kinase.

IT 116588-66-0P 736142-73-7P 736142-74-8P
 736142-79-3P 736142-87-3P 736142-88-4P
 736142-89-5P 736142-90-8P 736142-91-9P
 736142-92-0P 736142-93-1P 736142-94-2P
 736142-95-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of purines and pyrrolopyrimidines as selective kinase inhibitors)


RN 116588-66-0 CAPLUS

CN 9H-Purine, 6-chloro-9-methyl-8-phenyl- (9CI) (CA INDEX NAME)




RN 736142-73-7 CAPLUS

CN 9H-Purine, 9-methyl-8-phenyl-6-(phenylthio)- (9CI) (CA INDEX NAME)




RN 736142-74-8 CAPLUS

CN 9H-Purine, 6-[(4-fluorophenyl)thio]-9-methyl-8-phenyl- (9CI) (CA INDEX NAME)




RN 736142-79-3 CAPLUS

CN 9H-Purine, 6-(4-fluorophenyl)-9-methyl-8-phenyl- (9CI) (CA INDEX NAME)




RN 736142-87-3 CAPLUS

CN 9H-Purine, 6-chloro-9-methyl-8-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 736142-88-4 CAPLUS

CN 9H-Purine, 9-methyl-8-[4-(methylthio)phenyl]-6-(phenylthio)- (9CI) (CA INDEX NAME)




RN 736142-89-5 CAPLUS

CN 9H-Purine, 6-[(4-fluorophenyl)thio]-9-methyl-8-[4-(methylthio)phenyl]-
(9CI) (CA INDEX NAME)




RN 736142-90-8 CAPLUS

CN 9H-Purine, 6-chloro-9-methyl-8-[4-(methylsulfinyl)phenyl]- (9CI) (CA
INDEX NAME)




RN 736142-91-9 CAPLUS

CN 9H-Purine, 9-methyl-8-[4-(methylsulfinyl)phenyl]-6-(phenylthio)- (9CI)
(CA INDEX NAME)




RN 736142-92-0 CAPLUS

CN 9H-Purine, 6-[(4-fluorophenyl)thio]-9-methyl-8-[4-(methylsulfinyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 736142-93-1 CAPLUS

CN 9H-Purine, 6-chloro-9-methyl-8-[4-(methylsulfonyl)phenyl]- (9CI) (CA
INDEX NAME)




RN 736142-94-2 CAPLUS

CN 9H-Purine, 9-methyl-8-[4-(methylsulfonyl)phenyl]-6-(phenylthio)- (9CI)
(CA INDEX NAME)



RN 736142-95-3 CAPLUS
 CN 9H-Purine, 6-[(4-fluorophenyl)thio]-9-methyl-8-[4-(methylsulfonyl)phenyl]-
 (9CI) (CA INDEX NAME)



L49 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 3
 ACCESSION NUMBER: 2000:589999 CAPLUS
 DOCUMENT NUMBER: 133:177185
 TITLE: Preparation of 1-N-alkyl-N-arylpyrimidinamines as CRF
 inhibitors
 INVENTOR(S): Aldrich, Paul Edward; Arvanitis, Argyrios Georgios;
 Bakthavatchalam, Rajagopal; Beck, James Peter;
 Cheeseman, Robert Scott; Chorvat, Robert John;
 Gilligan, Paul Joseph; Hodge, Carl Nicholas;
 Wasserman, Zelda Rakowitz
 PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA
 SOURCE: U.S., 96 pp., Cont.-in-part of U.S. Ser. No. 315,660,
 abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6107301	A	20000822	US 1997-906349	19970805
CA 2174080	AA	19950420	CA 1994-2174080	19941006
HU 74464	A2	19961230	HU 1996-932	19941006
CN 1142817	A	19970212	CN 1994-194465	19941006

ZA 9407921	A	19960411	ZA 1994-7921	19941011
US 6342503	B1	20020129	US 1998-4150	19980107
PRIORITY APPLN. INFO.:			US 1993-134209	B2 19931012
			US 1994-297274	B2 19940826
			US 1994-315660	B2 19940929

OTHER SOURCE(S): MARPAT 133:177185

ED Entered STN: 24 Aug 2000

GI




AB The title compds. [I; Y = CR29; R1 = alkyl, alkenyl, alkynyl, etc.; R3 = aryl, haloalkyl, (un)substituted NH2, etc.; J, K, L = CH, CX1; M = CR5; V = N; Z = N; R4 = H, halo, halomethyl, etc.; R4 is taken together with R29 to form a 5-membered ring and is N; X = Cl, Br, I, etc.; X1 = H, Cl, Br, etc.; R5 = halo, alkyl, haloalkyl, etc.] and their pharmaceutically acceptable salts, useful in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsy, irritable bowel syndrome, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, drug and alc. withdrawal symptoms, drug addiction, inflammatory disorders, or fertility problems, were prepared and formulated. E.g., a 3-step synthesis of I [Y = V = N; Z = CH; J, K, L = CH; M = C(Me); X = Br; R1, R3, R4 = Me] which showed Ki of 501-2000 nM against CRF receptor binding, was given.

IT 169882-28-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-N-alkyl-N-arylpyrimidinamines as CRF inhibitors)

RN 169882-28-4 CAPLUS

CN 9H-Purine, 9-[2-bromo-4-(1-methylethyl)phenyl]-2-methyl-6-(4-morpholinyl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L49 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 1970:31840 CAPLUS

DOCUMENT NUMBER: 72:31840

TITLE: Analgesic and hypotensive 2-and 6-(4-substituted-1-piperazinyl) purines

INVENTOR(S): Regnier, Gilbert; Canevari, Roger; Le Douarec, Jean C.; Laubie, Michel

PATENT ASSIGNEE(S): Science Union et Cie., Societe Francaise de Recherche Medicale

SOURCE: U.S., 5 pp. CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3457263	A	19690722	US 1967-694357	19671229
GB 1165283	A	19690924	GB 1967-2446	19670117
BE 709014	A	19680705	BE 1968-709014	19680105
CH 490404	A	19700515	CH 1968-490404	19680112
FR 1550912	A	19681220	FR 1968-1550912	19680115
ES 349429	A1	19690401	ES 1968-349429	19680117
FR 7559	M	19691229	FR 1968-7559	19680329
			GB 1967-2446	A 19670117

PRIORITY APPLN. INFO.:

ED Entered STN: 12 May 1984

GI For diagram(s), see printed CA Issue.


AB To prepare title purines (I) chloro-substituted 4-amino-5-nitropyrimidines (II) were treated with N-monosubstituted piperazines (III) in a polar solvent, e.g. DMF (dimethylformamide) at 110-140° 14 hr in the presence of an acid acceptor, e.g. Na₂CO₃. The resulting IV is hydrogenated at room temperature under 2-10 atm in the presence of a catalyst, e.g. Raney Ni. The resulting diamino compound (V) is then cyclized to give I e.g. by heating it in an excess of ethyl orthoformate in the presence of Ac₂O 6 hr at 110-30°. Prepared were 2-[4-(diphenylmethyl)-1-piperazinyl]-purine, m. 210-12° (decomposition), bismethanesulfonate derivative m. 229-311°; 2-(4-cinnamylpiperazin-1-yl)purine, m. 260°; 6-[4-(diphenylmethyl)-1-piperazinyl]purine, m. 275-6°, bismethanesulfonate derivative, m. 230°. Other I prepared were (R, R₁, point of connection to the ring, and m.p. are given): piperonyl, H, 2, (di-HCl salt m. 195-6°); o-methoxyphenyl, H, 2, 239-40° (di-HCl salt 162-4°); 3,3-diphenylpropyl, H, 2, 88-91°;

2-pyrimidinyl, H, 2, 282-4°; 2-pyrimidinyl, Me, 2, 195-8°; diphenylmethyl, Me, 2, 193-5°; piperonyl, H, 6, 257°; cinnamyl, H, 6, 224°; phenylisopropyl, H, 6, 215-17°; o-methoxyphenoxyethyl, H, 6, 209°; 2-phenylethyl, H, 6, 243°; 3,3-diphenylpropyl, H, 6, 200°; piperonyl, Me, 2, [bis(methanesulfonate) m. 236-40°]; diphenylmethyl, HOCH₂CH₂, 2, 174°; phenylisopropyl, H, 2, (di-HCl salt m. 261-7°); 2-phenylethyl, H, 2, (di-HCl salt m. 258-63°); o-methoxyphenoxyethyl, H, 2, [(bismethanesulfonate) m. 208-17°]; piperonyl, HOCH₂CH₂, 2, (di-HCl m. 235-40°; piperonyl, allyl, 2, (di-HCl salt m. 204-12°); diphenylmethyl, allyl, 2, (di-HCl salt m. 257-59°; diphenylmethyl, piperonyl, [2-(bismethane sulfonate) m. 140-44°]; piperonyl, piperonyl, 2, (di-HCl salt 237-42°); piperonyl, 2,3-dihydroxypropyl, 2, 215-22° (decomposition); 2-pyrimidinyl, H, 6, >350°; o-methoxyphenyl, H, 6, [bis(methane sulfonate) m. 200-203°]; piperonyl, HOCH₂CH₂, 6, - (di-HCl salt m. 270°); piperonyl, piperonyl, 6, (di-HCl salt m. 139-49°); piperonyl, Me, 6, [bis(methanesulfonate) m. 197-200°]; diphenylmethyl, piperonyl, 6, 154°; diphenylmethyl, HOCH₂CH₂, 6, (di-HCl salt m. 213-17°); cinnamyl, piperonyl, 6, 136°; diphenylmethyl, 2,3-dihydroxypropyl, 6, 230-34°; m-(trifluoromethyl)phenyl, H, 6, 280-87°; 2-pyridinyl, H, 6, 300-305°. IV prepared were (R, R1, position of substitution, and m.p. given): piperonyl, H, 2, 157-8°; o-methoxyphenyl, H, 2, 176°; 3,3-diphenylpropyl, H, 2, 130°; 2-pyrimidinyl, H, 2, 180-81°; 2-pyrimidinyl, Me, 2, 231°; diphenylmethyl, Me, 2, 197°; diphenylmethyl, H, 2, 183°; piperonyl, H, 4, 162°; cinnamyl, H, 4, 155°; phenylisopropyl, H, 4, 168°; o-methoxyphenoxyethyl, H, 4, 110-12°; phenylethyl, H, 4, 180°; 3,3-diphenylpropyl, H, 4, 158°; piperonyl, Me, 2, 150°; diphenylmethyl, HOCH₂CH₂, 2, 163°; cinnamyl, H, 2, 160°; phenylisopropyl, H, 2, 190°; phenylethyl, H, 2, 180°; o-methoxyphenoxyethyl, H, 2, 120°; piperonyl, HOCH₂CH₂, 2, 109°; diphenylmethyl, allyl, 2, 134°; diphenylmethyl, piperonyl, 2, 173°; piperonyl, piperonyl, 2, 110° (decomposition); piperonyl, 2,3-dihydroxypropyl, 2, (di-HCl salt m. 210-19°). V prepared were (R, R1, position of substitution, and m.p. given): diphenylmethyl, H, 2, 222°; piperonyl, H, 2, 184°; o-methoxyphenyl, H, 2, (tri-HCl salt m. 163-5°); 3,3-diphenylpropyl, H, 2, [di-HCl salt m. 175-8° (decomposition)]; 2-pyrimidinyl, H, 2, 175°; 2-pyrimidinyl, Me, 2, 231°; diphenylmethyl, Me, 2, 256°; piperonyl, H, 4, 162°; cinnamyl, H, 4, 149°; phenylisopropyl, H, 4, 166°; o-methoxyphenoxyethyl, H, 4, 180°; phenylethyl, H, 4, 202°; 3,3-diphenylpropyl, H, 4, 170°; piperonyl, Me, 2, 140°; diphenylmethyl, HOCH₂CH₂, 2, 176°; cinnamyl, H, 2, (di-HCl salt m. 254-60°); phenylisopropyl, H, 2, 112°; phenylethyl, H, 2, 124-7° [tri-HCl salt m. 190° (decomposition)]; o-methoxyphenoxyethyl, H, 2, 106-110° (tri-HCl salt m. 218-223°); piperonyl, HOCH₂CH₂, 2, 94° [tri-HCl salt m. 200° (decomposition)]; piperonyl, allyl, 2, (an oil); diphenylmethyl, allyl, 2, 169°; diphenylmethyl, piperonyl, 2, (an oil); piperonyl, piperonyl, 2, (an oil); piperonyl, 2,3-dihydroxypropyl, 2, [tri-HCl salt m. 200° (decomposition)]. Other compds. prepared were 6-chloro-9-(hydroxyethyl)purine m. 160°, 6-chloro-9-piperonyl-purine m. 164°, and 6-chloro-9-methylpurine m. 140°; and these were used in the preparation of I. Toxicol. and pharmacol. studies have shown that they have a low toxicity and therapeutic properties as antihypertensive, analgesic, and central nervous system depressants. The LD₅₀ studied by i.p. administration in mice varies from 88-600 mg/kg and from 360 to over

2000 mg/kg for peroral administration.
IT **24932-83-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 24932-83-0 CAPLUS
CN 9H-Purine, 6-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-9-methyl-,
dimethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 37425-28-8
CMF C18 H20 N6 O2



CM 2

CRN 75-75-2
CMF C H4 O3 S



L49 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:588977 CAPLUS
DOCUMENT NUMBER: 143:115564
TITLE: Preparation of bicyclic imidazolyl pyrimidinones as
cannabinoid receptor ligands
INVENTOR(S): Carpino, Philip Albert
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061505	A1	20050707	WO 2004-IB4019	20041206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				


PRIORITY APPLN. INFO.:

US 2003-530012P


P 20031216

ED Entered STN: 08 Jul 2005

GI



I



II

AB Title compds. I [R1 = (un)substituted aryl, heteroaryl; R2 = -CH=CH-R2a, -CH2CH2R2a, (un)substituted aryl, heteroaryl; R2a = H, (un)substituted alkyl, aryl, etc.; R3 = H, alkoxy, (un)substituted alkyl or R3 together with R4 forms nitrogen containing 5-6 membered (un)saturated (un)substituted heterocycle; R4 = (un)substituted alkyl, aryl, heteroaryl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as ligands of the cannabinoid receptor. Thus, e.g., II was prepared by cyclization of 2-chloro-N-[4-chloro-6-(4-chlorophenylamino)-pyrimidin-5-yl]benzamide (preparation given) under acidic conditions followed by alkylation with 2-iodopropane. The activity of I was evaluated in binding assays and it was revealed that selected compds. of the invention displayed binding activities from 0.5 to 5000 nM. I as cannabinoid receptor ligand should prove useful in the treatment of eating disorders and obesity. Pharmaceutical compns. comprising I are disclosed.




IT **686344-46-7**, 9-(4-Chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-ol

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of bicyclic imidazolyl pyrimidin-4-ones as cannabinoid receptor ligands)

RN 686344-46-7 CAPLUS

CN 6H-Purin-6-one, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-1,9-dihydro-(9CI) (CA INDEX NAME)




IT 686344-49-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of bicyclic imidazolyl pyrimidin-4-ones as cannabinoid receptor ligands)

RN 686344-49-0 CAPLUS

CN 6H-Purin-6-one, 8-(2-chlorophenyl)-9-(4-chlorophenyl)-1,9-dihydro- (9CI)
(CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L49 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:493703 CAPLUS

DOCUMENT NUMBER: 141:54356

TITLE: Preparation of 1,3-dihydroimidazole fused-ring compounds as dipeptidylpeptidase IV (DPP-IV) inhibitors

INVENTOR(S): Kira, Kazunobu; Clark, Richard; Yoshikawa, Seiji; Uehara, Taisuke

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan

SOURCE: PCT Int. Appl., 143 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050656	A1	20040617	WO 2003-JP15402	20031202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2507763	AA	20040617	CA 2003-2507763	20031202
EP 1568699	A1	20050831	EP 2003-812368	20031202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016991	A	20051025	BR 2003-16991	20031202
PRIORITY APPLN. INFO.:			JP 2002-352186	A 20021204
			WO 2003-JP15402	W 20031202
OTHER SOURCE(S): MARPAT 141:54356				
ED Entered STN: 18 Jun 2004				
GI				



I



II


AB Title compds. I [wherein T1 = (un)substituted 1-2 nitrogen containing cyclic ring; X1 = (un)substituted alkyl, alkenyl, (hetero)allyl, etc.; X3 = O, S, (un)substituted amino; Z1 = N or CR₃; Z2, Z3 = independently N, CR₁, CO, NR₂; R₁-R₃, X2 = H, (un)substituted heterocyclic ring or (un)substituted alkylene; and their salts or hydrates thereof] were prepared as dipeptidylpeptidase IV (DPP-IV) inhibitors. For example, II•CF₃CO₂H was prepared in 6-steps synthesis starting from 3,7-dihydro-3-methyl-1H-purine-2,6-dione. I showed DPP-IV inhibition with the IC₅₀ value of 0.0029-89.5 μM. Thus, I and their pharmaceutical compns. are useful as DPP-IV inhibitors for the treatment of diabetes mellitus, obesity, hyperlipemia, and etc. (no data).

IT **121370-57-8P 705300-70-5P 705300-71-6P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 7,9-dihdropurine and 2,3-dihydroimidazo[4,5-c]pyridine derivs. as DPP-IV inhibitors)

RN 121370-57-8 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-(9-methyl-9H-purin-6-yl)-,

1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705300-70-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-(8-chloro-9-methyl-9H-purin-6-yl)-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 705300-71-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-(8,9-dihydro-9-methyl-8-oxo-7H-purin-6-yl)-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L49 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:196618 CAPLUS

DOCUMENT NUMBER: 132:237104

TITLE: Preparation of aryltetrahydropyridines as corticotropin releasing factor (CRF) receptor antagonists

INVENTOR(S): Nakazato, Atsuo; Kumagaya, Toshihito; Okubo, Taketoshi; Kataoka, Hiromi; Tomisawa, Kazuyuki

PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.

CODEN: JKXXAF



DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 2000086663	A2	20000328	JP 1998-255778	19980909
PRIORITY APPLN. INFO.:			JP 1998-255778	19980909
OTHER SOURCE(S):	MARPAT	132:237104		
ED Entered STN: 28 Mar 2000				
GI				



AB Aryltetrahydropyridines I, II [Ar1 = (un)substituted Ph, thienyl, furyl; Ar2 = (un)substituted Ph; Q = N, CH; XYZ = CN:CHN, CNR2CON; CN:NN, CCR3:CR2N, CNR2COCH2N, CNR2CH2CH2N, NN:CR2C, CSCR2:C; R1-R3 = H, lower alkyl], or their pharmacol. acceptable salts are prepared The aryltetrahydropyridines are useful for treatment of depression, Alzheimer's disease, hypertension, inflammation, cerebral infarction, etc. N-tert-butoxycarbonyl-3-hydroxy-3-(2-methylphenyl)piperidine (590 mg) was


treated with concentrated H₂SO₄ and successively treated with 200 mg 6-chloro-2-methyl-9-(2-methylthio-4-isopropylphenyl)purine to give 243 mg I [Ar₁ = 5-(2-MeC₆H₄), Ar₂ = 2-methylthio-4-isopropylphenyl, Q = N, XYZ = CN:CHN, R₁ = Me], which inhibited binding of ¹²⁵I-CRF to CRF receptor with IC₅₀ of 20.19 nM.

IT 251449-59-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryltetrahydropyridines as corticotropin releasing factor receptor antagonists)

RN 251449-59-9 CAPLUS

CN 9H-Purine, 6-[3,6-dihydro-5-(2-methylphenyl)-1(2H)-pyridinyl]-2-methyl-9-[4-(1-methylethyl)-2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



IT 251449-40-8P 251449-41-9P 251449-42-0P

251449-43-1P 251449-45-3P 251449-46-4P


251449-47-5P 251449-48-6P 251449-58-8P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aryltetrahydropyridines as corticotropin releasing factor receptor antagonists)


RN 251449-40-8 CAPLUS

CN 9H-Purine, 6-[4-(4-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-2-methyl-9-[4-(1-methylethyl)-2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 251449-41-9 CAPLUS

CN 9H-Purine, 6-[4-(3-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-2-methyl-9-[4-(1-methylethyl)-2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 251449-42-0 CAPLUS

CN 9H-Purine, 6-[4-(4-chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-2-methyl-9-[4-(1-methylethyl)-2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 251449-43-1 CAPLUS

CN 9H-Purine, 6-[4-(3-chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-2-methyl-9-[4-(1-methylethyl)-2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 251449-45-3 CAPLUS

CN 9H-Purine, 6-[3,6-dihydro-4-(2-methylphenyl)-1(2H)-pyridinyl]-2-methyl-9-[4-(1-methylethyl)-2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 251449-46-4 CAPLUS

CN 9H-Purine, 9-[2-bromo-4-(1-methylethyl)phenyl]-6-[4-(4-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 251449-47-5 CAPLUS

CN 9H-Purine, 9-[2-bromo-4-(1-methylethyl)phenyl]-6-[4-(4-chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 251449-48-6 CAPLUS

CN 9H-Purine, 9-[2-bromo-4-(1-methylethyl)phenyl]-6-(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 251449-58-8 CAPLUS

CN 9H-Purine, 6-[3-(4-fluorophenyl)-5,6-dihydro-1(2H)-pyridinyl]-2-methyl-9-[4-(1-methylethyl)-2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



L49 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:48722 CAPLUS

DOCUMENT NUMBER: 130:110276

TITLE: Preparation of imidazopyrimidines and imidazopyridines
for the treatment of neurological disordersINVENTOR(S): Wilde, Richard G.; Bakthavatchalam, Rajagopal; Beck,
James P.; Arvanitis, Argyrios G.

PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA

SOURCE: PCT Int. Appl., 325 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9901454	A1	19990114	WO 1998-US13913	19980702
W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2294117	AA	19990114	CA 1998-2294117	19980702
AU 9881819	A1	19990125	AU 1998-81819	19980702
AU 746706	B2	20020502		
ZA 9805818	A	20000110	ZA 1998-5818	19980702
EP 994877	A1	20000426	EP 1998-931795	19980702
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
EE 9900607	A	20000815	EE 1999-607	19980702
EE 4280	B1	20040415		
BR 9810508	A	20000905	BR 1998-10508	19980702
US 6143743	A	20001107	US 1998-109877	19980702
JP 2002507996	T2	20020312	JP 1999-507440	19980702
RU 2201929	C2	20030410	RU 2000-102649	19980702
TW 589309	B	20040601	TW 1998-87110857	19980702
US 6362180	B1	20020326	US 1998-208778	19981210
MX 9911669	A	20000531	MX 1999-11669	19991214
NO 9906483	A	20000302	NO 1999-6483	19991227
NO 316119	B1	20031215		
US 2003114468	A1	20030619	US 2001-53475	20011107
US 6642230	B2	20031104		
PRIORITY APPLN. INFO.:			US 1997-51628P	P 19970703
			US 1998-80665P	P 19980403
			US 1998-109877	A1 19980702
			WO 1998-US13913	W 19980702
			US 1998-208778	A3 19981210

OTHER SOURCE(S): MARPAT 130:110276

ED Entered STN: 25 Jan 1999

GI



AB The title compds. [I; A = N, CR7; B = N, CR8; at least one of A and B = N; D = aryl or heteroaryl attached through an unsatd. carbon atom; X = CHR9, NR10, O, S(O)n, a bond; n = 0-2; R1 = C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, etc.; R2 = C1-4 alkyl, C3-8 cycloalkyl, C2-4 alkenyl, etc.; R3, R7, R8 = H, halo, CN, etc.; R9, R10 = H, C1-4 alkyl, C3-6 cycloalkyl, etc.], corticotropin releasing factor (CRF) antagonists (no data) useful in treating psychiatric disorders and neurol. diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunol., cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathol. disturbance and stress in mammals, were prepared and formulated. Thus, a 6-step synthesis of purine II, starting with 5-amino-4,5-dichloropyrimidine and benzylamine, is given. Compds. I are effective at 0.01-10 mg/kg/day.


IT 219735-23-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazopyrimidines and imidazopyridines for the treatment of neurol. disorders)

RN 219735-23-6 CAPLUS

CN 9H-Purine, 6-(2,6-dimethoxy-3-pyridinyl)-8-ethyl-9-(1-methylbutyl)- (9CI)
(CA INDEX NAME)




REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L49 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1999:774194 CAPLUS
 DOCUMENT NUMBER: 132:9037
 TITLE: Aryltetrahydropyridines as corticotropin releasing factor antagonists
 INVENTOR(S): Nakazato, Atsuo; Kumagaya, Toshihito; Ohkubo, Taketoshi; Kataoka, Hiromi; Tomizawa, Kazuyuki
 PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11335376	A2	19991207	JP 1998-142620	19980525
PRIORITY APPLN. INFO.: MARPAT 132:9037			JP 1998-142620	19980525
OTHER SOURCE(S):				
ED Entered STN: 08 Dec 1999				
GI				



AB Title compds. I [Ar = (substituted) Ph, thienyl, furyl; R1 = H, lower alkyl, (substituted) amino; X1-X3 = H, halo, lower alkyl, lower alkoxy, lower alkylthio, lower alkylamino, pyrrolidino, piperidino, morpholino; Y1 = N, CR2; R2 = H, lower alkyl; Y2Y3 = N:N, N:CR3, NR4CO, CR5:CR6; R3-R6 = H, lower alkyl], useful for treatment of CRF-mediated diseases (e.g., depression, Alzheimer's disease, Parkinson's disease, Huntington's chorea, hypertension, cerebral infarction, etc.), are claimed.


N-tert-butoxycarbonyl-3-oxopiperidine was treated with o-MeC6H4MgBr to give 9.68 g N-tert-butoxycarbonyl-3-hydroxy-3-(2-methylphenyl)piperidine, which was treated with HCl in 1,4-dioxane and condensed with 6-chloro-2-methyl-9-(2-methylthio-4-isopropylphenyl)purine in (i-Pr)2NEt to give I (Ar = 5-C6H4Me-o, R1 = Me, X1 = 2-SMe, X2 = 4-i-Pr, X3 = H, Y1 = N, Y2Y3 = N:CH) (II). II inhibited CRF binding to rat frontal cortex membrane with IC50 of 20.19 nM.

IT 251449-40-8P 251449-41-9P 251449-42-0P
 251449-43-1P 251449-45-3P 251449-46-4P
 251449-47-5P 251449-48-6P 251449-58-8P
 251449-59-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of aryltetrahydropyridines as corticotropin releasing factor antagonists)


RN 251449-40-8 CAPLUS

CN 9H-Purine, 6-[4-(4-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-2-methyl-9-[4-(1-methylethyl)-2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 251449-41-9 CAPLUS

CN 9H-Purine, 6-[4-(3-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-2-methyl-9-[4-(1-methylethyl)-2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 251449-42-0 CAPLUS

CN 9H-Purine, 6-[4-(4-chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-2-methyl-9-[4-(1-methylethyl)-2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 251449-43-1 CAPLUS

CN 9H-Purine, 6-[4-(3-chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-2-methyl-9-[4-(1-methylethyl)-2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 251449-45-3 CAPLUS

CN 9H-Purine, 6-[3,6-dihydro-4-(2-methylphenyl)-1(2H)-pyridinyl]-2-methyl-9-[4-(1-methylethyl)-2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 251449-46-4 CAPLUS

CN 9H-Purine, 9-[2-bromo-4-(1-methylethyl)phenyl]-6-[4-(4-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 251449-47-5 CAPLUS

CN 9H-Purine, 9-[2-bromo-4-(1-methylethyl)phenyl]-6-[4-(4-chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 251449-48-6 CAPLUS

CN 9H-Purine, 9-[2-bromo-4-(1-methylethyl)phenyl]-6-(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 251449-58-8 CAPLUS

CN 9H-Purine, 6-[3-(4-fluorophenyl)-5,6-dihydro-1(2H)-pyridinyl]-2-methyl-9-[4-(1-methylethyl)-2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 251449-59-9 CAPLUS
 CN 9H-Purine, 6-[3,6-dihydro-5-(2-methylphenyl)-1(2H)-pyridinyl]-2-methyl-9-[4-(1-methylethyl)-2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



L49 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1987:18601 CAPLUS
 DOCUMENT NUMBER: 106:18601
 TITLE: Preparation of purine derivatives as pharmaceuticals
 INVENTOR(S): Yuki, Hiroshi; Sueoka, Hiroyuki; Yasumoto, Mitsuyoshi; Terasawa, Michio; Imayoshi, Tomonori
 PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61158983	A2	19860718	JP 1984-280057	19841228
JP 05028719	B4	19930427		
PRIORITY APPLN. INFO.:			JP 1984-280057	19841228
OTHER SOURCE(S):			CASREACT 106:18601	
ED Entered STN: 24 Jan 1987				
GI				



AB The title compds. (I; R = H, Ph, substituted Ph; R1 and R2 = H, alkyl, cycloalkyl, hydroxyalkyl, etc.; R3 and R4 = H or lower alkyl) are prepared as inflammation inhibitors, analgesics, antiallergy agents, and anticoagulants (no data). Thus, 4,5-diamino-6-(diethylamino)pyrimidine was refluxed with isonicotinic acid and POCl3 for 3 h to give 6-(diethylamino)-8-(4-pyridyl)purine. A tablet formulation containing I is


described.

IT 99492-21-4P 99492-27-0P 99492-28-1P
99492-29-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as pharmaceutical)


RN 99492-21-4 CAPLUS

CN 9H-Purin-6-amine, 9-ethyl-2-methyl-8-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 99492-27-0 CAPLUS

CN 9H-Purin-6-amine, N,N-diethyl-2,9-dimethyl-8-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 99492-28-1 CAPLUS

CN 9H-Purine, 2,9-dimethyl-6-(1-piperidinyl)-8-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 99492-29-2 CAPLUS

CN 9H-Purin-6-amine, N,N-diethyl-9-methyl-8-(4-pyridinyl)- (9CI) (CA INDEX NAME)




L49 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1986:33950 CAPLUS
 DOCUMENT NUMBER: 104:33950
 TITLE: Purine derivatives
 INVENTOR(S): Yuki, Hiroshi; Sueoka, Hiroyuki; Yasumoto, Mitsuyoshi;
 Terasawa, Michio; Imayoshi, Tomonori
 PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd. , Japan
 SOURCE: PCT Int. Appl., 20 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8503077	A1	19850718	WO 1984-JP633	19841228
W: US				
RW: AT, BE, DE, FR, GB, NL, SE				
JP 60260579	A2	19851223	JP 1984-4986	19840113
EP 168500	A1	19860122	EP 1985-900502	19841228
R: AT, BE, DE, FR, GB, NL, SE				
US 4728644	A	19880301	US 1985-768535	19850722
PRIORITY APPLN. INFO.:			JP 1984-4986	A 19840113
			WO 1984-JP633	W 19841228
OTHER SOURCE(S): CASREACT 104:33950				
ED Entered STN: 08 Feb 1986				
GI				



I




II

AB Title compds. I [R = H, alkyl, (un)substituted Ph; R1, R2 = H, alkyl, cycloalkyl, hydroxyalkyl, aminoalkyl, alkenyl, aralkyl; R1R2N = heterocyclic; R3, R4 = H, alkyl], useful as inflammation inhibitors, analgesics, antipyretics, antiallergics, and antithrombotics (no data), were prepared Thus, refluxing 5 g 4,5-diamino-6-diethylaminopyrimidine with 3.4 g isonicotinic acid in POCl3 for 3 h gave 3.4 g pyridylpurine II.

IT 99492-21-4P 99492-27-0P 99492-28-1P
 99492-29-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as medicine)


RN 99492-21-4 CAPLUS

CN 9H-Purin-6-amine, 9-ethyl-2-methyl-8-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 99492-27-0 CAPLUS

CN 9H-Purin-6-amine, N,N-diethyl-2,9-dimethyl-8-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 99492-28-1 CAPLUS

CN 9H-Purine, 2,9-dimethyl-6-(1-piperidinyl)-8-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 99492-29-2 CAPLUS

CN 9H-Purin-6-amine, N,N-diethyl-9-methyl-8-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L49 ANSWER 12 OF 17 USPATFULL on STN

Searched by Barb O'Bryen, STIC 2-2518

ACCESSION NUMBER: 2003:166610 USPATFULL
 TITLE: Imidazopyrimidines and imidazopyridines for the
 treatment of neurological disorders
 INVENTOR(S): Wilde, Richard Gerald, Newark, DE, UNITED STATES
 Bakthavatchalam, Rajagopal, Wilmington, DE, UNITED
 STATES
 Beck, James Peter, Smyrna, DE, UNITED STATES
 Arvanitis, Argyrios Georgios, Kennett Square, PA,
 UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003114468	A1	20030619
	US 6642230	B2	20031104
APPLICATION INFO.:	US 2001-53475	A1	20011107 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-208778, filed on 10 Dec 1998, GRANTED, Pat. No. US 6362180		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-51628P	19970703 (60)
	US 1998-80665P	19980403 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BRISTOL-MYERS SQUIBB PHARMA COMPANY, PATENT DEPARTMENT, P.O. BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
LINE COUNT:	12191	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Corticotropin releasing factor (CRF) antagonists of formula (I): ##STR1##	

and their use in treating psychiatric disorders and neurological
 diseases, anxiety-related disorders, post-traumatic stress disorder,
 supranuclear palsy and feeding disorders as well as treatment of
 immunological, cardiovascular or heart-related diseases and colonic
 hypersensitivity associated with psychopathological disturbance and
 stress in mammals.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 219735-23-6P

(preparation of imidazopyrimidines and imidazopyridines for the treatment of
 neurol. disorders)

RN 219735-23-6 USPATFULL

CN 9H-Purine, 6-(2,6-dimethoxy-3-pyridinyl)-8-ethyl-9-(1-methylbutyl)- (9CI)
 (CA INDEX NAME)



L49 ANSWER 13 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2002:63900 USPATFULL

TITLE: Imidazopyridines for the treatment of neurological disorders

INVENTOR(S): Wilde, Richard Gerald, Newark, DE, United States
Bakthavatchalam, Rajagopal, Wilmington, DE, United States
Beck, James Peter, Smyrna, DE, United States
Arvanitis, Argyrios Georgious, Kennett Square, PA, United States

PATENT ASSIGNEE(S): Bristol-Myers Squibb Pharma Company, Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6362180	B1	20020326
APPLICATION INFO.:	US 1998-208778		19981210 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-109877, filed on 2 Jul 1998		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-51628P	19970703 (60)
	US 1998-80665P	19980403 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Shah, Mukund J.	
ASSISTANT EXAMINER:	Liu, Hong	
LEGAL REPRESENTATIVE:	Browder, Monte R., Dolan, Peter L., Fuzail, Kalim S.	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	10329	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Corticotropin releasing factor (CRF) antagonists of formula (I):
##STR1##

and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 219735-23-6P

(preparation of imidazopyrimidines and imidazopyridines for the treatment of neurol. disorders)

RN 219735-23-6 USPATFULL

CN 9H-Purine, 6-(2,6-dimethoxy-3-pyridinyl)-8-ethyl-9-(1-methylbutyl)- (9CI)
(CA INDEX NAME)



L49 ANSWER 14 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2002:19321 USPATFULL

TITLE: 1N-alkyl-n-arylpyrimidinamines and derivatives thereof

INVENTOR(S): Aldrich, Paul Edward, Wilmington, DE, United States

Arvanitis, Argyrios Georgios, Kennett Square, PA, United States

Cheeseman, Robert Scott, Phoenixville, PA, United States

Chorvat, Robert John, West Chester, PA, United States

Christos, Thomas Eugene, Oxford, PA, United States

Gilligan, Paul Joseph, Wilmington, DE, United States

Grigoriadis, Dimitri Emil, Carlsbad, CA, United States

Hodge, Carl Nicholas, Wilmington, DE, United States

Krenitsky, Paul John, Newark, DE, United States

Scholfield, Everett Latham, New Castle, DE, United States

Tam, Sang William, Boston, MA, United States

Wasserman, Zelda Rakowitz, Wilmington, DE, United States

PATENT ASSIGNEE(S): DuPont Pharmaceuticals Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6342503	B1	20020129
APPLICATION INFO.:	US 1998-4150		19980107 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-315660, filed on 29 Sep 1994, now abandoned Continuation-in-part of Ser. No. US 1994-297274, filed on 26 Aug 1994, now abandoned Continuation-in-part of Ser. No. US 1993-134209, filed on 12 Oct 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Shah, Mukund J.		

ASSISTANT EXAMINER: Rao, Deepak R.
 LEGAL REPRESENTATIVE: Black, Robert W., Rubin, Kenneth B., Fuzail, Kalim S.
 NUMBER OF CLAIMS: 7
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
 LINE COUNT: 6014

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel compounds, compounds and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsy, irritable bowel syndrome, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, drug and alcohol withdrawal symptoms, drug addiction, **inflammatory** disorders, or fertility problems. The novel compounds provided by this invention are those of formula:
 ##STR1##

wherein R^{sup.1}, R^{sup.3}, R^{sup.4}, R^{sup.5}, Z, Y, V, X, X', J, K, L, and M are as defined herein.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **169882-28-4P**

(preparation of N-phenyl-2-pyrimidinamines and analogs as ACTH releasing factor antagonists)

RN 169882-28-4 USPTFULL

CN 9H-Purine, 9-[2-bromo-4-(1-methylethyl)phenyl]-2-methyl-6-(4-morpholinyl)-(9CI) (CA INDEX NAME)



L49 ANSWER 15 OF 17 USPTFULL on STN

ACCESSION NUMBER: 2000:150163 USPTFULL

TITLE: Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders

INVENTOR(S): Wilde, Richard Gerald, Newark, DE, United States
 Bakthavatchalam, Rajagopal, Wilmington, DE, United States

Beck, James Peter, Smyrna, DE, United States
 Arvanitis, Argyrios Georgious, Kennett Square, PA, United States

PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6143743		20001107
APPLICATION INFO.:	US 1998-109877		19980702 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-51628P	19970703 (60)
	US 1998-80665P	19980403 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Shah, Mukund J.	
ASSISTANT EXAMINER:	Liu, Hong	
LEGAL REPRESENTATIVE:	Browder, Monte R., O'Brien, Maureen P., Rubin, Kenneth B.	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
LINE COUNT:	13716	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Corticotropin releasing factor (CRF) antagonists of formula (I):
##STR1## and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 219735-23-6P

(preparation of imidazopyrimidines and imidazopyridines for the treatment of neurol. disorders)

RN 219735-23-6 USPATFULL

CN 9H-Purine, 6-(2,6-dimethoxy-3-pyridinyl)-8-ethyl-9-(1-methylbutyl)- (9CI)
(CA INDEX NAME)



L49 ANSWER 16 OF 17 USPATFULL on STN

ACCESSION NUMBER: 97:18161 USPATFULL

TITLE: Substituted aryl piperazines as neurokinin antagonists

INVENTOR(S): Chiang, Yuan-Ching P., Scotch Plains, NJ, United States

Finke, Paul E., Milltown, NJ, United States

Maccoss, Malcolm, Freehold, NJ, United States

Meurer, Laura C., Scotch Plains, NJ, United States

Miller, Daniel J., Edison, NJ, United States

Mills, Sander G., Woodbridge, NJ, United States

Robichaud, Albert J., Stirling, NJ, United States

Shah, Shrenik K., Metuchen, NJ, United States

PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S.)

corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5607936		19970304
APPLICATION INFO.:	US 1994-316013		19940930 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Gerstl, Robert		
LEGAL REPRESENTATIVE:	Panzer, Curtis C., Rose, David L.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2690		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are substituted aryl piperazines of Formula I ##STR1## are tachykinin receptor antagonists useful in the treatment of **inflammatory** diseases, pain or migraine, asthma and emesis. In particular compounds of Formula I are shown to be neurokinin antagonists.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 179249-74-2P 179249-75-3P

(preparation of arylpiperazines as neurokinin antagonists)

RN 179249-74-2 USPATFULL

CN Benzamide, N-[(2S)-2-(3,4-dichlorophenyl)-4-[4-(9-methyl-9H-purin-6-yl)-1-piperazinyl]butyl]-N,3,5-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179249-75-3 USPATFULL

CN Benzamide, N-[(2S)-2-(4-chlorophenyl)-4-[4-(9-methyl-9H-purin-6-yl)-1-piperazinyl]butyl]-N,3,5-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



88:13218 USPATFULL

Purine derivative and pharmaceutical composition

Yuki, Hiroshi, Toyonaka, Japan

Sueoka, Hiroyuki, Buzen, Japan

Yasumoto, Mitsuyoshi, Fukuoka, Japan

Terasawa, Michio, Nakatsu, Japan

Imayoshi, Tomonori, Nakatsu, Japan

Yoshitomi Pharmaceutical Industries, Ltd., Osaka, Japan
(non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4728644		19880301	
	WO 8503077		19850718	
APPLICATION INFO.:	US 1985-768535		19850722	(6)
	WO 1984-JP633		19841228	
			19850722	PCT 371 date
			19850722	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1984-4986	19840113
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Rizzo, Nicholas S.	
LEGAL REPRESENTATIVE:	Wenderoth, Lind & Ponack	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
LINE COUNT:	358	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Purine derivatives of the formula: ##STR1## wherein R is hydrogen, alkyl or phenyl which may be substituted by at least one halogen, lower alkyl or lower alkoxy; each of R.sup.1 and R.sup.2 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl, dialkylaminoalkyl, cyclic aminoalkyl, alkenyl or aralkyl, or R.sup.1 and R.sup.2 together with the adjacent nitrogen

atom form a heterocycle; and each of R.sup.3 and R.sup.4 is hydrogen or lower alkyl, and pharmaceutically acceptable acid addition salts thereof and/or hydrates, methods of preparing said compounds and pharmaceutical compositions containing said compounds. The purine compounds exhibit **antiinflammatory, analgesic, antipyretic** and **antiallergic** activity, and inhibitory activity on **platelet aggregation**, and are useful as drugs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 99492-21-4P 99492-27-0P 99492-28-1P

99492-29-2P

(preparation of, as medicine)


RN 99492-21-4 USPATFULL

CN 9H-Purin-6-amine, 9-ethyl-2-methyl-8-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 99492-27-0 USPATFULL

CN 9H-Purin-6-amine, N,N-diethyl-2,9-dimethyl-8-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 99492-28-1 USPATFULL

CN 9H-Purine, 2,9-dimethyl-6-(1-piperidinyl)-8-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 99492-29-2 USPATFULL

CN 9H-Purin-6-amine, N,N-diethyl-9-methyl-8-(4-pyridinyl)- (9CI) (CA INDEX NAME)




FILE 'HOME' ENTERED AT 16:16:19 ON 18 NOV 2005

=>

=> d stat que 142; d his full


L5 232082 SEA FILE=REGISTRY ABB=ON 333.446/RID
L8 STR



VAR G1=C/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS 6


STEREO ATTRIBUTES: NONE
L9 STR



VAR G1=C/N
VAR G2=O/S/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS 5

STEREO ATTRIBUTES: NONE
L38 STR



Ak @13

VAR G2=H/13
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 12
CONNECT IS E1 RC AT 13
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

ECOUNT IS M1 N AT 10



GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

L39 STR

Ak @13 G10 14



VAR G2=H/13

VAR G10=32/21

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 13

CONNECT IS E1 RC AT 26

CONNECT IS E1 RC AT 38

DEFAULT MLEVEL IS ATOM

GGCAT IS MCY UNS AT 39

GGCAT IS MCY UNS AT 40

DEFAULT ECLEVEL IS LIMITED

ECOUNT IS M1 N AT 24




GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 26

STEREO ATTRIBUTES: NONE

L40 STR

Ak @13 G10 14



VAR G2=H/13

VAR G10=7/32/21

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 13
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY UNS AT 12
GGCAT IS MCY UNS AT 26
GGCAT IS MCY UNS AT 38
GGCAT IS MCY UNS AT 39
GGCAT IS MCY UNS AT 40
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M1 N AT 10
ECOUNT IS M1 N AT 24

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 38

STEREO ATTRIBUTES: NONE

L42 864 SEA FILE=REGISTRY SUB=L5 SSS FUL (L38 OR ((L39 OR L40) AND (L8
OR L9)))

100.0% PROCESSED 180237 ITERATIONS
SEARCH TIME: 00.00.10

864 ANSWERS

(FILE 'HOME' ENTERED AT 14:50:38 ON 18 NOV 2005)

FILE 'CAPLUS' ENTERED AT 14:50:46 ON 18 NOV 2005

SET LINE 250
SET DETAIL OFF
E US2003-689381/AP, PRN 25
SET NOTICE 1000 SEARCH
L1 1 SEA ABB=ON US2003-689381/AP
SET NOTICE LOGIN SEARCH
SET LINE LOGIN
SET DETAIL LOGIN
D SCAN
SEL RN

FILE 'REGISTRY' ENTERED AT 14:51:56 ON 18 NOV 2005

L2 361 SEA ABB=ON (100-46-9/BI OR 1012-36-8/BI OR 1024-16-4/BI OR
1027-91-4/BI OR 103505-49-3/BI OR 106-47-8/BI OR 108-91-8/BI
OR 108-94-1/BI OR 109-01-3/BI OR 1126-09-6/BI OR 1192-30-9/BI
OR 128019-59-0/BI OR 134575-17-0/BI OR 138650-21-2/BI OR
18621-17-5/BI OR 34798-80-6/BI OR 3612-20-2/BI OR 393-52-2/BI
OR 394-39-8/BI OR 39906-04-2/BI OR 40320-60-3/BI OR 445-29-4/BI
OR 4637-24-5/BI OR 52-52-8/BI OR 5413-85-4/BI OR 557-66-4/BI
OR 592520-18-8/BI OR 593-51-1/BI OR 609-65-4/BI OR 686344-18-3/
BI OR 686344-19-4/BI OR 686344-20-7/BI OR 686344-21-8/BI OR
686344-22-9/BI OR 686344-23-0/BI OR 686344-24-1/BI OR 686344-25
-2/BI OR 686344-26-3/BI OR 686344-27-4/BI OR 686344-28-5/BI OR
686344-29-6/BI OR 686344-30-9/BI OR 686344-31-0/BI OR 686344-32
-1/BI OR 686344-33-2/BI OR 686344-34-3/BI OR 686344-35-4/BI OR
686344-36-5/BI OR 686344-37-6/BI OR 686344-38-7/BI OR 686344-39
-8/BI OR 686344-40-1/BI OR 686344-41-2/BI OR 686344-42-3/BI OR
686344-43-4/BI OR 686344-44-5/BI OR 686344-45-6/BI OR 686344-46
-7/BI OR 686344-47-8/BI OR 686344-48-9/BI OR 686344-49-0/BI OR
686344-50-3/BI OR 686344-51-4/BI OR 686344-52-5/BI OR 686344-53
-6/BI OR 686344-54-7/BI OR 686344-55-8/BI OR 686344-56-9/BI OR

686344-57-0/BI OR 686344-58-1/BI OR 686344-59-2/BI OR 686344-60-5/BI OR 686344-61-6/BI OR 686344-62-7/BI OR 686344-63-8/BI OR 686344-64-9/BI OR 686344-65-0/BI OR 686344-66-1/BI OR 686344-67-2/BI OR 686344-68-3/BI OR 686344-69-4/BI OR 686344-70-7/BI OR 686344-71-8/BI OR 686344-72-9/BI OR 686344-73-0/BI OR 686344-74-1/BI OR 686344-75-2/BI OR 686344-76-3/BI OR 686344-77-4/BI OR 686344-78-5/BI OR 686344-79-6/BI OR 686344-80-9/BI OR 686344-81-0/BI OR 686344-82-1/BI OR 686344-83-2/BI OR 686344-84-3/BI OR 686344-85-4/BI OR 686344-86-5/BI OR 686344-87-6/BI OR 686344-88-7/BI OR 686344-89-8/BI OR 686344-90-1/BI OR 686344-91-2/BI OR 686344-92-3/BI OR 686344-93-4/BI OR 686344-94-5/BI OR 686344-95-6/BI OR 686344-96-7/BI OR 686344-97-8/BI OR 686344-98-9/BI OR 686344-99-0/BI OR 686345-00-6/BI OR 686345-01-7/BI OR 686345-02-8/BI OR 686345-03-9/BI OR 686345-04-D SCAN

FILE 'LREGISTRY' ENTERED AT 15:02:04 ON 18 NOV 2005

L3 STR
L4 50 SEA SSS SAM L3
D STR RSD

FILE 'REGISTRY' ENTERED AT 15:03:09 ON 18 NOV 2005

E 333.446/RID
L5 232082 SEA ABB=ON 333.446/RID
L6 STR
L7 STR L6
L8 STR
L9 STR
L10 STR L6
L11 STR L6
L12 29 SEA SUB=L5 SSS SAM ((L7 OR L10) AND (L8 OR L9)) OR L11)
L13 788 SEA SUB=L5 SSS FUL ((L7 OR L10) AND (L8 OR L9)) OR L11)
SAVE TEMP L13 BER381FULL/A

FILE 'STNGUIDE' ENTERED AT 15:15:45 ON 18 NOV 2005

FILE 'REGISTRY' ENTERED AT 15:37:44 ON 18 NOV 2005

L14 ANALYZE L13 1- LC : 9 TERMS
D

FILE 'CAPLUS' ENTERED AT 15:39:20 ON 18 NOV 2005

L15 90 SEA ABB=ON L13
E ANTIINFL/CT
E E5+ALL
E E2+ALL
L16 37939 SEA ABB=ON ANTI-INFLAMMATORY AGENTS/CT
L17 87526 SEA ABB=ON INFLAMMATION/CW
L18 49905 SEA ABB=ON ANALGES?/OBI
E ANTIALLER/CT
E E6+ALL
E E2+ALL
L19 9202 SEA ABB=ON ALLERGY INHIBITORS/CT
E ANTIPYRETIC/CT
E E4+ALL
E E2+ALL
L20 4955 SEA ABB=ON ANTIPYRETICS/CT
L*** DEL 9 S L15 AND L16-L20
L21 22330 SEA ABB=ON PLATELET#/OBI(L) AGGREGAT?/OBI
L22 9 SEA ABB=ON L15 AND (L16 OR L17 OR L18 OR L19 OR L20 OR L21)

FILE 'TOXCENTER' ENTERED AT 15:44:34 ON 18 NOV 2005

L23 14 SEA ABB=ON L13
L24 193631 SEA ABB=ON ?INFLAMM?
L25 19392 SEA ABB=ON ?PYRETIC? OR ?PHLOGISTIC? OR ?THERMIC?
L26 56964 SEA ABB=ON ANALGES?
L27 101949 SEA ABB=ON ?ALLERG?
L28 15784 SEA ABB=ON PLATELET?(3A)AGGREGAT?
L29 2 SEA ABB=ON L23 AND (L24 OR L25 OR L26 OR L27 OR L28)
D SCAN

FILE 'USPATFULL' ENTERED AT 15:46:11 ON 18 NOV 2005

L30 26 SEA ABB=ON L13
L31 33986 SEA ABB=ON (ANTIINFLAMM? OR INFLAMM?)/IT, TI, AB, CLM
L*** DEL 2320 S (ANTIPYRETIC? OR PYRETIC? OR ANTIPHLOGISTIC? OR PHOLOGISTIC?
L32 2341 SEA ABB=ON (ANTIPYRETIC? OR PYRETIC? OR ANTIPHLOGISTIC? OR
PHLOGISTIC? OR ANTITHERMIC? OR THERMIC?)/IT, TI, AB, CLM
L33 11382 SEA ABB=ON ANALGES?/IT, TI, AB, CLM
L34 11903 SEA ABB=ON (ALLERG? OR ANTIALLERG?)/IT, TI, AB, CLM
L35 3813 SEA ABB=ON (PLATELET#(3A)AGGREGAT?)/IT, TI, AB, CLM
L36 6 SEA ABB=ON L30 AND (L31 OR L32 OR L33 OR L34 OR L35)

FILE 'STNGUIDE' ENTERED AT 15:49:07 ON 18 NOV 2005

FILE 'REGISTRY' ENTERED AT 15:49:38 ON 18 NOV 2005
D STAT QUE L13

FILE 'CAPLUS' ENTERED AT 15:49:39 ON 18 NOV 2005
D QUE NOS L22

FILE 'USPATFULL' ENTERED AT 15:49:40 ON 18 NOV 2005
D QUE NOS L36

FILE 'TOXCENTER' ENTERED AT 15:49:41 ON 18 NOV 2005
D QUE NOS L29

L37 FILE 'CAPLUS, USPATFULL, TOXCENTER' ENTERED AT 15:49:51 ON 18 NOV 2005
14 DUP REM L22 L36 L29 (3 DUPLICATES REMOVED)
ANSWERS '1-9' FROM FILE CAPLUS
ANSWERS '10-14' FROM FILE USPATFULL
D IBIB ED ABS HITSTR 1-14

FILE 'HOME' ENTERED AT 15:50:16 ON 18 NOV 2005
D STAT QUE L13
D SAVED

L38 FILE 'REGISTRY' ENTERED AT 16:10:36 ON 18 NOV 2005
STR L11
L39 STR L10
L40 STR L7
L41 32 SEA SUB=L5 SSS SAM (L38 OR ((L39 OR L40) AND (L8 OR L9)))
L42 864 SEA SUB=L5 SSS FUL (L38 OR ((L39 OR L40) AND (L8 OR L9)))
SAVE TEMP L42 BER381FULL/A
D QUE NOS L13

FILE 'CAPLUS' ENTERED AT 16:13:32 ON 18 NOV 2005
D QUE NOS L22
L43 11 SEA ABB=ON L42 AND (L16 OR L17 OR L18 OR L19 OR L20 OR L21)

L44 FILE 'REGISTRY' ENTERED AT 16:14:10 ON 18 NOV 2005
122 SEA ABB=ON L42 AND TOXCENTER/LC

FILE 'USPATFULL' ENTERED AT 16:14:21 ON 18 NOV 2005
L45 31 SEA ABB=ON L42
D QUE NOS L36
L46 7 SEA ABB=ON L45 AND (L31 OR L32 OR L33 OR L34 OR L35)

FILE 'TOXCENTER' ENTERED AT 16:14:52 ON 18 NOV 2005
L47 17 SEA ABB=ON L44
D QUE NOS L29
L48 3 SEA ABB=ON L47 AND (L24 OR L25 OR L26 OR L27 OR L28)

FILE 'REGISTRY' ENTERED AT 16:15:24 ON 18 NOV 2005
D STAT QUE L42

FILE 'CAPLUS' ENTERED AT 16:15:46 ON 18 NOV 2005
D QUE NOS L43

FILE 'USPATFULL' ENTERED AT 16:15:47 ON 18 NOV 2005
D QUE NOS L46

FILE 'TOXCENTER' ENTERED AT 16:15:47 ON 18 NOV 2005
D QUE NOS L48

FILE 'CAPLUS, USPATFULL, TOXCENTER' ENTERED AT 16:15:47 ON 18 NOV 2005
L49 17 DUP REM L43 L46 L48 (4 DUPLICATES REMOVED)
ANSWERS '1-11' FROM FILE CAPLUS
ANSWERS '12-17' FROM FILE USPATFULL
D IBIB ED ABS HITSTR 1-17

FILE 'HOME' ENTERED AT 16:16:19 ON 18 NOV 2005
D STAT QUE L42

FILE HOME

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Nov 2005 VOL 143 ISS 22
FILE LAST UPDATED: 17 Nov 2005 (20051117/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 NOV 2005 HIGHEST RN 868355-11-7

DICTIONARY FILE UPDATES: 17 NOV 2005 HIGHEST RN 868355-11-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE LREGISTRY
LREGISTRY IS A STATIC LEARNING FILE

NEW CAS INFORMATION USE POLICIES, ENTER HELP USAGETERMS FOR DETAILS.

FILE STNGUIDE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Nov 11, 2005 (20051111/UP).

FILE TOXCENTER

FILE COVERS 1907 TO 15 Nov 2005 (20051115/ED)

This file contains CAS Registry Numbers for easy and accurate substance
identification.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TOXCENTER has been enhanced with new files segments and search fields.
See HELP CONTENT for more information.

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the
MeSH 2005 vocabulary. See <http://www.nlm.nih.gov/mesh/> and
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html for a
description of changes.

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 17 Nov 2005 (20051117/PD)
FILE LAST UPDATED: 17 Nov 2005 (20051117/ED)
HIGHEST GRANTED PATENT NUMBER: US6966066
HIGHEST APPLICATION PUBLICATION NUMBER: US2005257307
CA INDEXING IS CURRENT THROUGH 17 Nov 2005 (20051117/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 17 Nov 2005 (20051117/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2005

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=>